PDF
Full
Outline
To evaluate the efficacy and safety of anlotinib combined with gemcitabine + docetaxel as second-line or later therapy in patients with lung metastasis of osteosarcoma.
Case data of 23 patients with lung metastasis of osteosarcoma received anlotinib combined with gemcitabine + docetaxel as second-line or later therapy in the department of oncology of Shanghai Sixth People’s Hospital from January 2016 to December 2022 were analysed retrospectively. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate, disease control rate (DCR) and safety.
In the 23 patients with lung metastasis of osteosarcoma, 17 patients (74%)achieved stable disease and 6 patients (26%) achieved progress disease, with DCR 74%. Median PFS was 10.8 months (95% CI: 1.4 to 20.2 months). All 23 patients experienced adverse reactions. Grade 3 or 4 adverse reactions included thrombocytopenia (17%)，hypothyroidism (9%), hypertension (4%), hand-foot reaction (4%), fatigue (4%), diarrhea (4%), leukopenia (4%), and pneumothorax (4%).
Anlotinib combined with gemcitabine + docetaxel as second-line or later therapy can be used as an effective treatment with manageable toxicities for patients with lung metastasis of osteosarcoma.
PDF
118
57
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
